Kevin Joseph Harrington

58PUBLICATIONS
504CO-AUTHORS
Biologically active moleculesCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (58)

|Oct 15, 2026
Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes anti-tumour immunity in combination with radiotherapy.

|Oct 12, 2026
Addition of chemotherapy to radiotherapy promotes progenitor-exhausted CD8⁺ T-cell clonal dominance in head and neck cancer.

|Oct 01, 2026
Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study.

|Sep 15, 2026
Amivantamab plus pembrolizumab in previously untreated recurrent/metastatic head and neck squamous cell cancer: Results from the phase 1b/2 OrigAMI-4 study.

|Aug 19, 2026
Danvatirsen plus Pembrolizumab versus Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (PEMDA-HN): A Randomized, Phase II Trial.

|Jul 30, 2026
"SMAC"-Down for the Apoptosis-Restoring Drug, Xevinapant: What Does Its Story Reveal?

Pageof 10

Frequent Collaborators

17 joint publications

Alan Melcher

13 joint publications

Emmanuel Patin

10 joint publications

Pablo Nenclares

10 joint publications

Charleen Ml Chan Wah Hak